STUDY PROTOCOL article
Front. Psychiatry
Sec. Schizophrenia
This article is part of the Research TopicExploring Neuromodulation and Neuroimaging Techniques for Psychiatric Disorders: Insights from Preclinical and Clinical StudiesView all 5 articles
A Randomized Controlled Trial of Adjunctive iTBS Targeting the Dorsomedial Prefrontal Cortex for Anhedonia in Schizophrenia: Rationale and Protocol Design
Provisionally accepted
- 1Southwest Medical University, Luzhou, China
- 2Zigong City Mental Health Center, Zigong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Anhedonia, a core negative symptom of schizophrenia, refers to the inability to experience pleasure from normally enjoyable activities. It significantly worsens prognosis and remains poorly addressed by current treatments. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown potential in treating anhedonia in depression and other disorders; however, its application to anhedonia in schizophrenia remains underexplored. This study aimed to evaluate the efficacy of rTMS targeting the dorsomedial prefrontal cortex (DMPFC) on anhedonia in patients with schizophrenia, and to explore its correlation with cognitive function and prefrontal activity. Methods: The present study is a randomized controlled trial that will include 82 patients with schizophrenia who meet DSM-5 diagnostic criteria and have a score of ≥12 on the Snaith-Hamilton Pleasure Scale (SHAPS). Eligible participants will be randomly allocated in a 1:1 ratio to either active or sham rTMS stimulation groups. The active group will receive a high-frequency rTMS intervention using an intermittent theta-burst stimulation (iTBS) protocol (20 trains x 10 pulses at 5 Hz, with an intensity of 90% of resting motor threshold) administered twice daily for 15 days. The sham group will receive a sham-stimulation regimen with the same parameters. All participants will be assessed using both the SHAPS and the Scale for the Assessment of Negative Symptoms (SANS) at three time points: baseline (T0), immediately post-treatment (T1), and 4-week follow-up (T2). In addition, the Wisconsin Card Sorting Test (WCST) and the dynamics of prefrontal oxygenated hemoglobin (Δoxy-Hb) monitored by functional near-infrared spectroscopy (fNIRS) , will be assessed at T0, T1, and T2. Ethics and dissemination: The trial protocol complies with the principles of the Declaration of Helsinki and has been approved by the Ethics Committee of Zigong Mental Health Center (approval number: 20250801). The findings of this trial will be published and made publicly accessible in a peer-reviewed journal. Discussion: If the iTBS protocols targeting the DMPFC lead to positive changes in anhedonia symptoms in patients with schizophrenia, this would provide a new intervention strategy for negative symptoms. Furthermore, leveraging neuroimaging evidence from such studies could help optimize rTMS target selection and overall treatment strategies. Trial registration:ChiCTR2500107965
Keywords: Schizophrenia, Anhedonia, rTMS, iTBS, dmPFC, fNIRS, Cognitivefunctions
Received: 16 Sep 2025; Accepted: 06 Nov 2025.
Copyright: © 2025 Wu, Yu, He, Liu, Fan, Xu, Den, Long, Liu, Liu and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bo Liu, liubo2511@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.